LCG
MYGN icon

Luxor Capital Group’s Myriad Genetics MYGN Stock Holding History

Luxor Capital Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,815,341
Closed -$62.1M – 46
2014
Q1 		$62.1M Sell
1,815,341
-1,483,107
-45% -$45.9M 1.22% 25
2013
Q4 		$69.2M Buy
3,298,448
+2,894,448
+716% +$73.2M 1.11% 19
2013
Q3 		$9.49M Buy
+404,000
New +$11.5M 0.13% 31

Other funds holding MYGN

RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $24B AUM 39.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Luxor Capital Group's MYGN Position: Q2 2014 in Review

Luxor Capital Group sold out of Myriad Genetics (MYGN) in Q2 2014, closing a stake of 1,815,341 shares — an estimated $62.1M sold.

Luxor Capital Group first reported a position in MYGN in Q3 2013 and held it in 3 quarters. The position peaked at $69.2M in Q4 2013. 284 funds tracked by Wall St. Rank hold MYGN as of Q2 2014.

  • Luxor Capital Group reported no remaining Myriad Genetics position as of Q2 2014 after selling out during the quarter.
  • Luxor Capital Group sold 1,815,341 Myriad Genetics shares in Q2 2014, an estimated $62.1M.
  • Luxor Capital Group first reported a position in Myriad Genetics in Q3 2013 and held it in 3 quarters.
  • Luxor Capital Group's Myriad Genetics position peaked at $69.2M in Q4 2013.
  • 284 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2014.

Based on Luxor Capital Group's 13F filing for Q2 2014, filed 14 Aug 2014.